medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical
diagnosis of frontotemporal dementia

Author: Vicent Llorca-Bofí
Tutors: Ignacio Illán-Gala and Rafael Blesa González
Degree in Medicine
Faculty of Medicine – Unitat Docent Sant Pau
Universitat Autònoma de Barcelona
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ACKNOWLEDGEMENTS
First of all, I would like to thank Dr. Ignacio Illán-Gala and Dr. Rafael Blesa for tutoring me during
the elaboration of the present work, for all the wisdom and knowledge they have shared, for the
dedication and teaching spirit they have proven to have within, and for introducing me in the world of
the biomedical research. I would like to thank all the members of the Memory Unit in Hospital Sant
Pau for giving me the opportunity to collaborate in this project.

ii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ABSTRACT
Objective: To investigate the sex-related differences in the clinical diagnosis of the frontotemporal
dementia (FTD) in the Hospital Sant Pau, Barcelona.
Methods: We selected patients diagnosed of FTD from the SPIN cohort (Hospital Sant Pau) and
analyzed clinical data. Participants were classified in three different groups according to the clinical
presentation. We compared clinical data between sexes in each group.
Results: A total of 193 patients were included: 41% in the behavioural group, 47% in the motor group
and 12% in the language group. We found a higher proportion of men in the behavioural group when
compared to the motor and language groups (χ-squared=27.042; p<0.001). Within the behavioural
group: women presented with a lower MMSE at diagnosis (Mann-Whitney U=262.0; p=0.041) and
women received a previous diagnosis of depression more frequently than men (χ-squared= 7.393;
p=0.007). In the motor and language groups no sex-related differences were observed.
Conclusions: We observed sex-related differences in the diagnosis of FTD that were restricted to
behavioural presentation group.

Key words: frontotemporal dementia; behavioural variant; diagnosis; sex-related differences.

iii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

RESUMEN
Objetivo: Investigar las diferencias relacionadas con el sexo en el diagnóstico clínico de la demencia
frontotemporal (DFT) en el Hospital Sant Pau, Barcelona.
Material y método: Se seleccionaron pacientes con diagnóstico de DFT de la cohorte SPIN (Hospital
Sant Pau) y se analizaron los datos clínicos. Los participantes se clasificaron en tres grupos de acuerdo
con la presentación clínica. Se compararon los datos clínicos entre los sexos de cada grupo.
Resultados: Se incluyeron 193 pacientes: 41% en el grupo conductual, 47% en el grupo motor y 12%
en el grupo lingüístico. Se encontró una mayor proporción de hombres en el grupo conductual en
comparación con los grupos motor y del lenguaje (χ-squared=27.042; p<0.001). En el grupo
conductual: las mujeres presentaron un MMSE más bajo en el momento del diagnóstico (MannWhitney U=262.0; p=0.041) y recibieron un diagnóstico previo de depresión con mayor frecuencia
que los hombres (χ-squared= 7.393; p=0.007). En los grupos motor y del lenguaje no se observaron
diferencias relacionadas con el sexo.
Conclusiones: En este estudio observamos diferencias relacionadas con el sexo en el diagnóstico de
DFT que se limitaron al grupo de presentación conductual.

Palabras clave: demencia frontotemporal; variante conductual; diagnóstico; diferencias de sexo.

iv

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

RESUM
Objectiu: Investigar les diferències relacionades amb el sexe en el diagnòstic clínic de la demència
frontotemporal (DFT) a l’Hospital Sant Pau, Barcelona.
Material i mètode: Es van seleccionar pacients amb diagnòstic de DFT de la cohort SPIN (Hospital
Sant Pau) i es van analitzar les dades clíniques. Els participants es van classificar en tres grups d'acord
amb la presentació clínica. Es van comparar les dades clíniques entre els sexes de cada grup.
Resultats: Es van incloure 193 pacients: 41% en el grup conductual, 47% en el grup motor i 12% en
el grup lingüístic. Es va trobar una major proporció d'homes en el grup conductual en comparació amb
els grups motor i de llenguatge (χ-squared=27.042; p<0.001). Al grup conductual: les dones van
presentar un MMSE més baix al moment del diagnòstic (Mann-Whitney U=262.0; p=0.041) i van
rebre un diagnòstic previ de depressió amb major freqüència que els homes (χ-squared= 7.393;
p=0.007). Als grups motor i del llenguatge no es van observar diferències relacionades amb el sexe.
Conclusions: En aquest estudi observem diferències relacionades amb el sexe en el diagnòstic de DFT
que es van limitar al grup de presentació conductual.

Paraules clau: demència frontotemporal; variant conductual; diagnòstic; diferències de sexe.

v

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

Table of contents

ABSTRACT ....................................................................................................................................................... iii
RESUMEN ......................................................................................................................................................... iv
RESUM ............................................................................................................................................................... v
Table of contents ................................................................................................................................................ vi
1.

Research question ........................................................................................................................................ 1

2.

Background.................................................................................................................................................. 1
Introduction ..................................................................................................................................................... 1
Epidemiology .................................................................................................................................................. 3
Diagnosis ......................................................................................................................................................... 3
Treatment......................................................................................................................................................... 4
Prognosis ......................................................................................................................................................... 4

3.

Justification.................................................................................................................................................. 5

4.

Hypotheses and objectives .......................................................................................................................... 5

5.

Material and methods .................................................................................................................................. 6
Participants and study design .......................................................................................................................... 6
CSF analysis .................................................................................................................................................... 7
Variables of interest......................................................................................................................................... 7
Statistical analysis ........................................................................................................................................... 8
Ethical considerations...................................................................................................................................... 8
Diffusion mechanisms ..................................................................................................................................... 8

6.

Results ......................................................................................................................................................... 9
Sample composition ........................................................................................................................................ 9
Patients’ characteristics ................................................................................................................................... 9
Clinical characteristics by sex ....................................................................................................................... 10

7.

Discussion.................................................................................................................................................. 13

Bibliography ...................................................................................................................................................... 16
ANNEXES ........................................................................................................................................................... i
ANNEX 1: Project timeline................................................................................................................................. ii
ANNEX 2: MMSE (Mini-mental state examination)......................................................................................... iii
ANNEX 3: Rascovsky criteria ........................................................................................................................... iv
ANNEX 4: Informed consent .............................................................................................................................. v

vi

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

1. Research question
Our aim was to study the sex-related differences in the diagnosis of the main frontotemporal dementia
(FTD)-related syndromes (behavioural, language and motor presentation). We carried out a crosssectional study to answer the following questions: (i) Are there sex-related differences in the diagnosis
of any of the clinical presentations of FTD? (ii) Are there sex-related differences in the frequency of
previous psychiatric diagnoses across the clinical presentations of FTD? (iii) Are there sex-related
differences in the clinical stage of FTD (as measured by the MMSE) at diagnosis across the different
clinical presentations of FTD?

2. Background
Introduction
Frontotemporal Dementia is characterized by the degeneration of the frontal and/or temporal lobes and
encompasses multiple clinical syndromes. Patients can be subclassified according to the predominant
symptoms at disease onset: (i) prominent behavioural symptoms, (ii) prominent motor impairment,
(iii) or a progressive language impairment.
First, the patients with a prominent behavioural syndrome fit into the clinical label of the behavioural
variant of FTD (bvFTD). The bvFTD is characterized by a prominent personality change with relative
preservation of memory, perception, visuospatial skills and praxis. Although clinical symptoms at
diagnosis are variable, they often include prominent behavioural change including symptoms such as:
disinhibition (usually with impairment of social behaviour), impulsivity (including careless decisions),
apathy (or lack of motivation to engage previously rewarding activities), lack of empathy, change in
eating behaviour and cognitive symptoms related to executive dysfunction. The clinical criteria for the
diagnosis of the bvFTD have shown good diagnostic accuracy in a large multicenter cohort of patients
with pathology-proven FTD (1). Moreover, current diagnostic criteria allow the use of biomarkers to
1

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

increase diagnostic certainty (2) and define two categories: possible bvFTD, more sensitive but less
specific; and highly probable bvFTD, less sensitive but more specific.
Patients with the bvFTD are often misdiagnosed with psychiatric disorders because neuropsychiatric
symptoms of the bvFTD are easily mistaken for those of a primary psychiatric disorder. Thus, the
diagnosis of bvFTD presents a special challenge in terms of differential diagnosis with female patients
at highest risk for misdiagnosis (3,4).
Another group of patients display prominent motor symptoms at presentation. This group of patients
include patients within the FTD-Amyotrophic Lateral Sclerosis continuum (FTD-ALS) and the
Progressive Supranuclear Palsy-Corticobasal Degeneration continuum (PSP-CBD). Between 10% and
25% of patients with ALS (characterized by progressive muscle wasting, hyperreflexia, and spasticity)
present with FTD clinical phenotypes (progressive aphasia, language impairment, and executive
dysfunction) forming the FTD-ALS continuum. On the other hand, patients within the PSP-CBD
continuum share motor features such as extrapyramidal symptoms, stiffness and bradykinesia
combined with behavioural, motor, and language symptoms.
Finally, a third group of patients display prominent language impairment at presentation. These
patients are classified within the clinical umbrella of primary progressive aphasia (PPA). The PPA can
be further subclassified into two FTD-related subgroups according to the current diagnostic criteria:
the semantic variant [svPPA] and the nonfluent variant [nfvPPA]) (5). Patients with svPPA have a
variety of language difficulties, including naming difficulties, impaired understanding of word
meaning, and use of substitute words. However, speech is fluent and there is preservation of other
cognitive domains. Conversely, patients with nfvPPA show effortful speech with syntactic impairment
and preservation of semantic knowledge. Speech output becomes increasingly difficult and in the later
stages the patient may become mute.

2

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

All these clinical syndromes are included in the umbrella term FTD, as they share a partiallyoverlapping pattern of neurodegeneration across frontotemporal structures.
Figure 1: Predominant clinical phenotypes of FTD.

Frontotemporal dementia syndromes
Behavioural
presentation

bvFTD

Language
presentation
(PPA)

Motor
presentation

FTD-ALS

PSP-CBS

nfvPPA

svPPA

Key: bvFTD = behavioural variant of frontotemporal dementia; FTD-ALS = frontotemporal dementia – amyotrophic lateral sclerosis
continuum; PSP-CBD= progressive supranuclear palsy – corticobasal degeneration continuum; nfvPPA = nonfluent variant primary
progressive aphasia; svPPA = semantic variant primary progressive aphasia.

Epidemiology
FTD is a common cause of degenerative dementia, especially among young patients, second only to
Alzheimer disease (AD) (6). His prevalence ranges from 15 to 22 per 100,000 persons (7). FTD has
been classically described as early-onset dementia (age <65 years) compared to other dementias (8,9),
but it is more prevalent among 60-69 and only 13% have an onset before age 50 (10). Younger onset
may be due in part to heavy genetic loading for FTD, with up to 50% of cases being familial and up to
40% autosomal-dominant in nature (10).
Sex differences in prevalence have been reported with a 3-to-4.7–fold greater prevalence in males than
in females (11,12) although this sex distribution has not been supported by all studies (13,14) and the
existence of sex-related differences in the diagnosis of FTD syndromes remain controversial.
Importantly, some studies have reported sex-related differences in the diagnosis of some of the FTD
clinical subgroups, such as the bvFTD patients, but not in language of motor presentations (15).
Diagnosis
The diagnosis of FTD requires a thorough history, including a detailed family history of dementia, and
physical examination. It is particularly important to dissect the timing and rate of progression of
symptoms, and behavioural and personality changes over the previous months or years. Clinical
3

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

presentation varies across FTD syndromes (Table 1). Clinical consensus criteria for diagnosing FTD
syndromes have been recently updated (1,5,16–19). Neuroimaging and cerebrospinal fluid (CSF)
biomarkers are included in the diagnosis criteria and they are helpful in the diagnosis and excluding
other aetiologies.
Mini-Mental State Examination (MMSE) is a simply score commonly used in dementia screening in
clinical practice. It has recently demonstrated to be a sensitive index of disease progression in bvFTD
(20).
Table 1: Frequency of features of frontotemporal dementia syndromes and Alzheimer disease. Modified from Cardarelly R. et al (21).

Relative frequency of syndrome features

Frontotemporal dementia syndromes
Behavioural
Motor
Language
FTDPSPbvFTD
nfvPPA svPPA
ALS
CBS

Behavioural or personality changes

+++

+++

AD

++

+

++

+

+++

++

+

+

+++

++
++

+++

+

Extrapyramidal features

+

Rigidity, bradykinesia

+

+

Loss of object knowledge and comprehension deficits

+

++

Effortful speech, agrammatism, telegraphic speech

+

++

++

+++

+

+

Memory loss

+

+

+

++

++

+++

Key: bvFTD = behavioural variant of frontotemporal dementia; FTD-ALS= frontotemporal dementia – amyotrophic lateral sclerosis
continuum; PSP-CBS continuum = progressive supranuclear palsy – corticobasal degeneration continuum; nfvPPA = non-fluent variant
primary progressive aphasia; svPPA = semantic variant primary progressive aphasia; AD = Alzheimer disease.

Treatment
There is no specific cure for FTD; treatment is focused on symptom management and support for
patients, families, and caregivers (22). However, disease-modifying treatments for FTD are expected
to be developed (23). An accurate clinical diagnosis will be essential for the selection of participants
in future clinical trials. Nonetheless, we should take into account the existence of sex-related biases in
FTD diagnosis that might hamper the treatment of some patients (24).
Prognosis
There is limited research on the prognosis of FTD. In a retrospective longitudinal in 2005 (25), median
survival was 8.7 years (±1.2 years) in patients with FTD compared with 11.8 years (±0.6 years) in
4

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

patients with Alzheimer disease. Survival after diagnosis has been previously demonstrated
independent of sex by some studies (4) but not all studies support that result and data remains
controversial (24).

3. Justification
FTD is the second leading cause of early-onset dementia, and its economic burden is substantial (26).
One of the key factors to this burden may be the earlier age at onset, typically occurring during patients’
or caregivers’ peak earning years. Some studies have suggested that patients with bvFTD are
frequently misdiagnosed as having a psychiatric disorder, specially in women (15). The identification
of sex-related biases for the diagnosis of bvFTD is essential to improve the recognition of this disease
by physicians (24). This would become particularly important when disease modifying treatments
become available. However, previous studies assessing sex-related differences in the diagnosis of the
bvFTD are scarce and no previous studies have studied sex-related differences in the diagnosis of all
the clinical syndromes within the FTD clinical umbrella (that mean including the behavioural,
language and motor presentations).

4. Hypotheses and objectives
We hypothesized that there may be sex-related differences in the diagnosis across the main clinical
presentations of FTD (behavioural, language and motor). Specifically, we hypothesized that sexrelated differences in the diagnosis of FTD may be restricted to the bvFTD group. These differences
may be related to social factors influencing the diagnosis of psychiatric and neurodegenerative diseases
in middle-aged and older adults. Consequently, women with bvFTD may be misdiagnosed with a
psychiatric diagnosis more frequently than men and thus, they might be diagnosed with bvFTD at a
more advanced stage.
The specific questions that we wanted to answer in our study were: (i) Are there sex-related differences
in the diagnosis of any of the clinical presentations of FTD? (ii) Are there sex-related differences in
5

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

the frequency of previous psychiatric diagnoses across the clinical presentations of FTD? (iii) Are
there sex-related differences in the clinical stage of FTD (as measured by the MMSE) at diagnosis
across the different clinical presentations of FTD?

5. Material and methods
A cross-sectional descriptive design with patients with FTD diagnosis in the Sant Pau Initiative on
Neurodegeneration (SPIN cohort: https://santpaumemoryunit.com/our-research/spin-cohort/) from
2010 to 2017 was performed. Data were collected from the electronic database. A time line was
performed to guarantee the development of the study (ANNEX 1)
Participants and study design
In the SPIN cohort, patients were recruited between January 2010 and December 2017 at the Memory
Unit at Hospital Sant Pau (Barcelona, Spain) as part of the cohort. Briefly, patients underwent a
uniform set of clinical, neuropsychological, neuroimaging, and laboratory assessments, including CSF
sampling. Subjects were referred by general physicians or neurologists because of cognitive or
behavioural complaints. All the patients included in the SPIN cohort (Figure 2) were screened to fit
the eligible inclusion criteria for participation:
1. FTD diagnosis: bvFTD (1), svPPA (5), nfvPPA (5), PSP (16), CBS (21) or ALS (18,19).
2. MMSE at diagnosis.
3. CSF with biomarkers.
The exclusion criterion was AD pathophysiology: CSF t-tau/Aß1-42 ratio > 0.52 (27).
In order to simplify the analysis, patients were grouped into behavioural presentation (bvFTD),
language presentation (svPPA and nfvPPA) and motor presentation (ALS, PSP and CBS). Patients
with bvFTD were evaluated firstly as a single group and then they were separated on two subgroups
based on Rascovsky criteria (1): possible and highly probable bvFTD.
6

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia
Figure 2: Flow chard of the study patients.

Patients in the SPIN cohort
From 2010 to 2017
(n=6443)
Other clinical syndromes:
-Alzheimer disease
-Lewy body dementia
-Vascular dementia
-Psychiatric
-Controls
(n=6242)
FTD clinical criteria
(n=201)
AD CSF biomarker profile
(n=8)
193 patients
Biomarkers’ supported FTD diagnosis

CSF analysis
Availability of CSF was required for the inclusion in the study. All biomarkers were analyzed at the
Sant Pau Memory Unit Laboratory with commercially available enzyme-linked immunosorbent assay
(ELISA) kits determining levels of Aβ1-42 (Innotest β-amyloid 1-42; Fujirebio Europe) and t-Tau
(Innotest hTAU Ag, Fujirebio-Europe) following previously reported methods and manufacturer’s
instructions (27–29).
Variables of interest
The clinical characteristics were collected prospectively at the time of diagnosis using a homogenized
questionnaire for the whole SPIN cohort. Study variables were selected from the electronic database
of the SPIN cohort. We selected the MMSE (ANNEX 2) as it has proved to be a simple and reliable
measure of the general cognitive impairment in patients with FTD (20). We also studied the presence
of the different behavioural symptoms considered in the bvFTD criteria to assess the behavioural
profile of each patient (ANNEX 3) (1), the presence of previous psychiatric history (depression,
bipolar and psychotic) and familiar history of neurodegenerative disease. Age of onset was the age of

7

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

the patient when the earliest symptom of dementia was noted by the patient or carers and it was
retrieved during the first visit to our center. Time to diagnosis was defined as the difference between
age at which an FTD-related syndrome was diagnosed and age of onset using data from the electronic
database.
Statistical analysis
The categorical demographic characteristics of the participants were presented according to frequency
and percentage, and the median was used for the continuous variables due to a skewed nature. We used
non-parametric test because the variables MMSE and time to diagnosis showed no normality in
Kolmogorov-Smirnov test (D=0.251, p<0.001 and D=0.169, p<0.001 respectively) and the number of
participants in the language group was inferior to 30. In order to compare the differences between
sexes, a χ-squared test was used for categorical variables and the Mann-Whitney U test was used for
testing the continuous variables. A Pearson correlation coefficient for the correlation between time
from onset to diagnosis and MMSE was calculated. A p-value less than 0.05 was defined as statistically
significant. All computations and graphics were performed with use of SPSS-IBM (ver. 23).
Ethical considerations.
The study was approved by the local ethics committee and was conducted in accordance with the
Declaration of Helsinki. All participants gave their written informed consent (ANNEX 4) to participate
in the study.
Diffusion mechanisms
The main diffusion mechanism planned for this investigation is the publication of the study in the
European Journal of Neurology (Q1, IF:3.956), one of the leading journals in the field of clinical
neurology in Europe. Publication in other scientific journals may also be contemplated, especially
those concerning specifically clinical neurology in Spain. These include: Neurologia (Q3, IF:2.103)
and Revista de Neurologia (Q3, IF:0.743).

8

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

6. Results
Sample composition
We included a total of 193 patients, 79 (40.9%) females and 114 (59.1%) males, with FTD (Figure 3,
Table 2): 80 (41.4%) with bvFTD, 90 (46.6%) with motor presentation and 23 (12%) with language
presentation.
Figure 3: Distribution of the FTD-related syndromes in the SPIN cohort.

Patients’ characteristics
A) Main clinical diagnosis in each FTD group.
Behavioural and Motor presentations were the commonest presentations. bvFTD was the second
presentation in frequency with also two thirds of the patients classified in the high probability group
(Table 4). Within the motor presentation group, most of the patients belonged to the FTD-ALS
continuum. Language was the less common presentation, involving mostly nfvPPA, and with a high
percentage of women.

9

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

B) Demographic and clinical differences between the FTD groups.
Table 2 summarizes the demographic and clinical differences between clinical groups based on
clinical features at presentation.
We observed a higher frequency of men in the bvFTD group when compared to the motor and language
groups (χ-squared=27.042; p<0.001). When we separated the bvFTD group in possible and highly
probable subgroups using Rascovsky criteria we found a male predominance in both subgroups (χsquared=11.645, p=0.001; χ-squared=6.897, p=0.009 respectively). The MMSE score at diagnosis was
lower and the time from symptom onset to diagnosis was higher in the bvFTD when compared to
motor and language groups (Mann-Whitney U=2905.5, p=0.019; Mann-Whitney U=3423.5, p=0.004,
respectively). Conversely, the age at symptom onset was similar between groups (Mann-Whitney
U=4432.0; p=0.818).
Table 2: Clinical data of the patients included.

Behavioural
presentation

Motor & Language
presentations

N (% of total sample)
Women

80 (41.4)
16 (20.0)

113 (58,6)
63 (55,7)

p<0.001*

Age at onset, y
MMSE at diagnosis
Time to diagnosis, y

64.2 (9.9)
25 (6.2)
3.7 (3.4)

66.0 (11.8)
27 (5.9)
2.5 (3.4)

p=0.818
p=0.019*
p=0.004*

Phenotypes, n
-Possible
-Highly probable
-FTD-ALS continuum
-FTD-CBD continuum
-nfvPPA
-svPPA

25 (33.8)
49 (66.2)
-

71 (62.8)
19 (16.8)
16 (14.2)
7 (6.2))

p-value

Quantitative variables are shown as median (standard deviation). Categorical variables are described with the number of subjects
and the relative frequency (%). *= significant differences (p<0.05). Key: MMSE = mini-mental state examination; nfvPPA =
nonfluent variant primary progressive aphasia; svPPA = semantic variant primary progressive aphasia; FTD-ALS continuum =
frontotemporal dementia – amyotrophic lateral sclerosis continuum; PSP = progressive supranuclear palsy; CBS = corticobasal
syndrome.

Clinical characteristics by sex
In the behavioural presentation the age of onset showed no differences related to sex. When we
compared the severity of presentation at diagnosis, female MMSE was lower (Mann-Whitney
U=262.0; p=0.041) than male (Figure 4A). The behavioural profile showed no sex-related differences.
10

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

The overall psychiatric history also showed no significant differences. But separating patients by
specific psychiatric diagnosis, women with bvFTD received a depression diagnosis more often (χsquared= 7.393; p=0.007) than men in the same group (Table 3). Family history of neurodegeneration
showed no influence by sex in any of the three presentations. The time from the onset of symptoms to
diagnosis was no different between the sexes. To better understand the relationship between the time
and the MMSE we analyzed the relationship between both variables, but the time was not correlated
with a worse MMSE in either women or men (r=0.003, p=0.443; r=-0.098, p=0.003 respectively).
To obtain a purer sample of bvFTD patients, we separated patients using biomarkers (Table 4). The
possible subgroup may be contaminated by psychiatric patients. In contrast, the highly probable
subgroup has a purer diagnosis. In the highly probable subgroup we found lower MMSE (Figure 4B)
and higher depression diagnosis (Mann-Whitney U=92.5, p=0.048; χ-squared= 8.361, p=0.004
respectively) in women.
The motor and language presentations showed no sex-related differences in any of the clinical data
analyzed.
Figure 4: Sex differences in MMSE of: A) FTD presentations, B) behavioural presentation.

Key: MMSE= mini-mental state examination, FTD = frontotemporal dementia, bvFTD= behavioural presentation, *= p<0.05.

11

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

Table 3: Sex differences in the three FTD presentations.

Behavioural presentation
Motor presentation
Language presentation
N=80 (41.4%)
N=90 (46.6%)
N=23 (12%)
Female
Male
Female
Male
Female
Male
16 (20.0%) 64 (80.0%) p-value 47 (52.2%) 43 (47.8%) p-value 16 (69.6%) 7 (30.4%) p-value
Age of onset, y

64.4 (8.8) 64.0 (10.2) 0.493 67.5 (12.2) 61.9 (12.5) 0.080

66.5 (7.5) 63.7 (10.3) 0.548

MMSE, /30

22.0 (4.4)

26.0 (5.0) 0.041* 26.0 (5.2)

27.0 (3.9)

0.194

26.0 (5.5) 28.0 (10.6) 0.368

14 (87.5)
14 (87.5)
11 (68.8)
12 (75.0)
12 (75.0)
5 (31.3)

58 (90.6)
52 (81.3)
46 (71.9)
44 (68.8)
44 (68.8)
30 (46.9)

0.709
0.556
0.805
0.626
0.626
0.260

15 (31.9)
13 (27.7)
6 (12.8)
6 (12.8)
6 (12.8)
23 (48.9)

7 (16.3)
7 (16.3)
6 (14.0)
6 (14.0)
3 (7.0)
18 (41.9)

0.085
0.195
0.869
0.869
0.489
0.501

4 (25.0)
9 (56.3)
0 (0)
1 (6.3)
1 (6.3)
6 (37.5)

2 (28.6)
2 (28.6)
0 (0)
0 (0)
1 (14.3)
3 (42.9)

1.000
0.371
1.000
0.526
1.000

9 (56.3)

20 (31.3)

0.063

16 (34.8)

9 (20.9)

0.146

5 (35.7)

1 (16.7)

0.613

10 (62.5)
1 (6.7)
2 (13.3)
6 (37.5)

17 (26.6)
3 (4.7)
2 (3.2)
33 (52.4)

0.007*
0.753
0.165
0.288

16 (34.8)
0 (0)
1 (2.1)
14 (34.1)

8 (18.6)
1 (2.3)
0 (0)
11 (26.8)

0.086
1.000
0.089
0.472

6 (40.0)
0 (0)
14 (87.5)
8 (50.0)

0 (0)
1 (16.7)
5 (71.4)
2 (40.0)

0.260
0.300
0.557
1.000

4.3 (2.2)

3.6 (3.7)

0.918

2.3 (3.0)

3.2 (4.2)

0.315

2.0 (2.3)

3.2 (1.41)

0.249

Behavioural profile, n
- Disinhibition
- Apathy
- Empathy
- Ritual
- Food oral
- Executive
Psychiatric history,
n
- Depression
- Bipolar
- Psychotic
Familiar history, n
Time to diagnosis, y

Quantitative variables are shown as median (standard deviation). Categorical variables are described with the number of subjects
and the relative frequency (%). *= significant differences (p<0.05). Key: MMSE = mini-mental state examination.

Table 4: Characteristics in bvFTD grouped in possible and highly probable diagnostic subgroups using Rascovsky criteria.

Age of onset, y
MMSE, /30
Behavioural profile, n
- Disinhibition
- Apathy
- Empathy
- Ritual
- Food oral
- Executive
Psychiatric history, n
- Depression
- Bipolar
- Psychotic
Familiar history, n
Time to diagnosis, y

Possible bvFTD
N=25 (33.8%)
Female
Male
3 (12%)
22 (88%)
p-value
66.8 (7.2)
66.6 (10.4)
0.676
22.0 (4.0)
26.0 (2.9)
0.499
2 (66.7)
3 (100)
2 (66.7)
2 (66.7)
2 (66.7)
1 (33.3)
2 (66.7)
2 (66.7)
0 (0)
1 (33.3)
1 (33.3)
5,0 (2.4)

19 (86.4)
20 (90.9)
15 (68.2)
14 (63.6)
15 (68.2)
14 (63.6)
6 (27.3)
7 (31.8)
2 (9.1)
1 (4.5)
11 (50.0)
3.8 (4.9)

0.422
1.000
1.000
1.000
1.000
0.543
0.231
0.530
1.000
0.230
1.000
0.065

Highly probable bvFTD
N=49 (66.2%)
Female
Male
12 (24.5%) 37 (75.5%) p-value
62.0 (9.9)
62.6 (9.9)
0.727
21.0 (4.4)
26.0 (5.9)
0.048*
12 (100)
11 (91.7)
9 (75.0)
10 (83.3)
10 (83.3)
4 (33.3)
7 (58.3)
8 (66.7)
1 (9.1)
1 (9.1)
4 (33.3)
3.5 (2.0)

35 (94.6)
28 (75.7)
29 (78.4)
29 (78.4)
26 (70.3)
15 (40.5)
12 (32.4)
8 (21.6)
1 (2.7)
1 (2.8)
18 (50.0)
3.6 (3.0)

1.000
0.237
0.232
0.711
0.373
0.656
0.110
0.004*
0.410
0.417
0.316
0.561

Quantitative variables are shown as median (standard deviation). Categorical variables are described with the number of subjects
and the relative frequency (%). *= significant differences (p<0.05). Key: MMSE = mini-mental state examination.

12

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

7. Discussion
We report sex-related differences in the clinical diagnosis of the bvFTD in a large sample of FTD
patients from a referral center of neurodegenerative dementias in Catalonia. Importantly, the observed
sex-related differences were restricted to the bvFTD. In the bvFTD, women showed a higher frequency
of previous psychiatric diagnosis when compared to men. This finding may suggest that women that
are diagnosed of bvFTD in our environment receive a previous psychiatric diagnosis more frequently
than men. Furthermore, we found lower MMSE at diagnosis in women diagnosed of bvFTD when
compared to men. This finding may suggest that women that are finally diagnosed of bvFTD may be
referred to our centre at a later disease stage than men. These results underscore a possible bias towards
the misdiagnosis of psychiatric illness in the bvFTD, as suggested by a previous study in the United
States of America (15).
In our cohort, we found a male predominance restricted to the bvFTD. Then, we analyzed that group
using biomarkers classification according to Rascovsky criteria. The proportion of possible bvFTD
and highly probable bvFTD was similar to the observed in previous well-characterized cohorts (30).
In booth subgroups (possible and highly probable bvFTD) we found a male predominance. Finally, we
found a similar behavioural profile in men and women. Thus, we did not find sex-related differences
in the phenotype of the bvFTD in our center. Taken together, these findings suggest a sex-related bias
in the identification of bvFTD before the referral of the patients to our center.
It is worth noting that bvFTD symptoms may mimic psychiatric symptoms, leading to psychiatric
misdiagnosis (3,4). Family members and doctors that are not familiar with the diagnosis of the bvFTD
may overlook the typical change in personality of patients with the bvFTD and misdiagnose bvFTD
patients with psychiatric diagnoses. This is a key factor that may contribute to delay the diagnosis of
a neurodegenerative disease (31). As mentioned before, our findings regarding a higher frequency of
psychiatric misdiagnosis in women with bvFTD agree with those described in other well-characterized
cohorts in the United States of America (15). However, it should be noted that unlike previous studies,
13

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

our study has been carried out in a European population with a public healthcare system and universal
access. This is an important difference because in a public system the time from the onset of symptoms
to the consultation, the access to the health system and the quality of care received are independent of
the patient's socioeconomic level and may decrease healthcare access bias (32).
The MMSE is a useful tool to measure the cognitive impairment in bvFTD, as it has been shown in
previous studies (20). The MMSE score was lower in female patients with bvFTD but not in the other
presentations. We found higher impairment restricted to highly probable bvFTD subgroup. The time
from the estimated symptom onset to diagnosis varied between syndromes. Concretely, we found a
higher time to diagnosis in the bvFTD. This finding may suggest a delay in the diagnosis of the bvFTD.
However, this difference was not significant when comparing women and men. We found that the
MMSE impairment was not associated with more time to diagnosis in women. Although one might
initially presume that MMSE impairment implies a longer time from onset to diagnosis, this hypothesis
is contradicted by our data. However, it should be noted that the time from symptom onset to the
diagnosis is an estimation that can be influenced by the caregivers’ ability to identify the earliest
changes in the patient’s personality. Thus, this estimation can be influenced by several factors escaping
out of our control. By the contrary, the MMSE is an objective score widely used by neurologists.
Not all the studies support the existence of sex-related differences in the bvFTD (24). This may be due
to socio-cultural factors (many family members do not consider personality change as a disease),
factors in the differential diagnosis (diagnosing FTD syndromes may be difficult for physicians and
general neurologists), or factors from the patient's neurological study (the lack of use of biomarkers to
support the diagnosis). Another possibility is that women may display more aggressive phenotypes of
FTD. However, there is no evidence to support this hypothesis in the literature. Taken together, our
results highlight the importance of identifying diagnosis biases of FTD. Further studies should
specifically address the factors contributing to sex-related differences in the diagnosis of FTD among
general neurologist and psychiatrists.
14

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

The main strength of this study is the deep phenotyping of the patients included. CSF biomarkers ruled
out AD in the patients included in this study. Thus, we have low probability of AD misdiagnosis.
Furthermore, in our cohort we considered the wide range of FTD-related syndromes. Finally, our study
is the first to assess sex-related differences in the diagnosis of FTD in European population with a
public healthcare system.
This study has also some limitations. Although we think that a cross-sectional design is the most
feasible way to study sex-related differences in the clinical presentation of FTD, our cohort is made
up of patients from a single center. Thus we cannot exclude the possibility of a selection bias (33).
Further multicenter studies are needed to improve our understanding of potential sex-related
differences in the diagnosis of FTD in our environment.
In conclusion, the bvFTD is more frequently diagnosed in men in our environment, and women are
diagnosed at a more advanced stage with a higher frequency of previous psychiatric diagnosis. In sum,
our results suggest that women diagnosed with the bvFTD may be more frequently misdiagnosed with
psychiatric conditions in our environment. This work highlights the importance of sex-related biases
for the diagnosis of the bvFTD and the need of educational activities to improve the knowledge about
FTD among general practitioners and the population in our environment. Further multicenter studies
are needed to confirm our observations and disentangle the underpinnings of sex-related biases in the
diagnosis of the bvFTD.

15

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

Bibliography
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

Rascovsky K, Hodges JR, Knopman D,
Mendez MF, Kramer JH, Neuhaus J, et al.
Sensitivity of revised diagnostic criteria for
the behavioural variant of frontotemporal
dementia. Brain. 2011;134(9):2456-77.
Lleó A, Irwin DJ, Illán-Gala I, McMillan
CT, Wolk DA, Lee EB, et al. A 2-Step
Cerebrospinal Algorithm for the Selection
of Frontotemporal Lobar Degeneration
Subtypes. JAMA Neurol. 2018;
Pressman PS, Miller BL. Diagnosis and
management
of
behavioral
variant
frontotemporal dementia. Biol Psychiatry.
2014;75(7):574-81.
Block NR, Sha SJ, Karydas AM, Fong JC,
De May MG, Miller BL, et al.
Frontotemporal Dementia and Psychiatric
Illness: Emerging Clinical and Biological
Links in Gene Carriers. Am J Geriatr
Psychiatry. 2016;24(2):107-16.
Gorno-Tempini ML, Hillis AE, Weintraub
S, Kertesz A, Mendez M, Cappa SF, et al.
Classification of primary progressive
aphasia and its variants. Neurology.
2011;76(11):1006-14.
Knopman DS, Roberts RO. Estimating the
Number of Persons with Frontotemporal
Lobar Degeneration in the US Population. J
Mol Neurosci. 2011;45(3):330-5.
Coyle-Gilchrist ITS, Dick KM, Patterson K,
Vázquez Rodríquez P, Wehmann E, Wilcox
A, et al. Prevalence, characteristics, and
survival
of
frontotemporal
lobar
degeneration
syndromes.
Neurology.
2016;86(18):1736-43.
Neary D, Snowden J, Mann D.
Frontotemporal dementia. Lancet Neurol.
2005;4(11):771-80.
Ratnavalli E, Brayne C, Dawson K, Hodges
JR. The prevalence of frontotemporal
dementia. Neurology. 2002;58(11):161521.
Onyike CU, Diehl-Schmid J. The
epidemiology of frontotemporal dementia.
Int Rev Psychiatry. 2013;25(2):130-7.

12.

13.

14.

15.

16.

17.

18.

16

Mercy L, Hodges JR, Dawson K, Barker
RA, Brayne C. Incidence of early-onset
dementias in Cambridgeshire, United
Kingdom. Neurology. 2008;71(19):1496-9.
Bernardi L, Frangipane F, Smirne N, Colao
R, Puccio G, Curcio SAM, et al.
Epidemiology
and
genetics
of
frontotemporal dementia: a door-to-door
survey in Southern Italy. Neurobiol Aging.
2012;33(12):2948.e1-2948.e10.
Rosso SM, Kaat LD, Baks T, Joosse M, de
Koning
I,
Pijnenburg
Y,
et al.
Frontotemporal
dementia
in
The
Netherlands: patient characteristics and
prevalence estimates from a populationbased study. Brain. 2003;126(9):2016-22.
Seelaar H, Rohrer JD, Pijnenburg YAL, Fox
NC, van Swieten JC. Clinical, genetic and
pathological
heterogeneity
of
frontotemporal dementia: a review. J
Neurol
Neurosurg
Psychiatry.
2011;82(5):476-86.
Woolley JD, Khan BK, Murthy NK, Miller
BL, Rankin KP. The Diagnostic Challenge
of
Psychiatric
Symptoms
in
Neurodegenerative Disease. J Clin
Psychiatry. 2011;72(2):126-33.
Höglinger GU, Respondek G, Stamelou M,
Kurz C, Josephs KA, Lang AE, et al.
Clinical
diagnosis
of
progressive
supranuclear palsy: The movement disorder
society
criteria.
Mov
Disord.
2017;32(6):853-64.
Armstrong MJ, Litvan I, Lang AE, Bak TH,
Bhatia KP, Borroni B, et al. Criteria for the
diagnosis of corticobasal degeneration.
Neurology. 2013;80(5):496-503.
Brooks BR, Miller RG, Swash M, Munsat
TL, World Federation of Neurology
Research Group on Motor Neuron Diseases.
El Escorial revisited: revised criteria for the
diagnosis of amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Other Motor
Neuron Disord. 2000;1(5):293-9.

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia
19.

20.

21.

22.

23.

24.

25.

26.

27.

Niven E, Newton J, Foley J, Colville S,
Swingler R, Chandran S, et al. Validation of
the Edinburgh Cognitive and Behavioural
Amyotrophic Lateral Sclerosis Screen
(ECAS): A cognitive tool for motor
disorders. Amyotroph Lateral Scler Front
Degener. 2015;16(3-4):172-9.
Ranasinghe KG, Rankin KP, Lobach I V,
Kramer JH, Sturm VE, Bettcher BM, et al.
Cognition
and
neuropsychiatry
in
behavioral variant frontotemporal dementia
by
disease
stage.
Neurology.
2016;86(7):600-10.
Cardarelli R, Kertesz A, Knebl JA.
Frontotemporal dementia: a review for
primary care physicians. Am Fam
Physician. 2010;82(11):1372-7.
Buoli M, Serati M, Caldiroli A, Galimberti
D,
Scarpini
E,
Altamura
AC.
Pharmacological
Management
of
Psychiatric Symptoms in Frontotemporal
Dementia: A Systematic Review. J Geriatr
Psychiatry Neurol. 2017;30(3):162-9.
Young JJ, Lavakumar M, Tampi D,
Balachandran S, Tampi RR. Frontotemporal
dementia: latest evidence and clinical
implications. Ther Adv Psychopharmacol.
2018;8(1):33-48.
Podcasy JL, Epperson CN. Considering sex
and gender in Alzheimer disease and other
dementias. Dialogues Clin Neurosci.
2016;18(4):437-46.
Roberson ED, Hesse JH, Rose KD, Slama
H, Johnson JK, Yaffe K, et al.
Frontotemporal dementia progresses to
death faster than Alzheimer disease.
Neurology. 2005;65(5):719-25.
Galvin JE, Howard DH, Denny SS,
Dickinson S, Tatton N. The social and
economic burden of frontotemporal
degeneration.
Neurology.
2017;89(20):2049-56.
Alcolea D, Carmona-Iragui M, SuárezCalvet M, Sánchez-Saudinós MB, Sala I,
Antón-Aguirre S, et al. Relationship
between β-Secretase, inflammation and core
cerebrospinal
fluid
biomarkers
for
Alzheimer’s disease. J Alzheimers Dis.

28.

29.

30.

31.

32.

33.

34.

35.

2014;42(1):157-67.
Alcolea D, Vilaplana E, Suárez-Calvet M,
Illán-Gala I, Blesa R, Clarimón J, et al. CSF
sAPPβ, YKL-40, and neurofilament light in
frontotemporal
lobar
degeneration.
Neurology. 2017;89(2):178-88.
Alcolea D, Martínez-Lage P, Sánchez-Juan
P, Olazarán J, Antúnez C, Izagirre A, et al.
Amyloid precursor protein metabolism and
inflammation markers in preclinical
Alzheimer
disease.
Neurology.
2015;85(7):626-33.
Ranasinghe KG, Rankin KP, Pressman PS,
Perry DC, Lobach I V., Seeley WW, et al.
Distinct Subtypes of Behavioral Variant
Frontotemporal Dementia Based on Patterns
of Network Degeneration. JAMA Neurol.
2016;73(9):1078.
Robinson L, Tang E, Taylor J-P. Dementia:
timely diagnosis and early intervention.
BMJ. 2015;350:h3029.
GBD 2015 Healthcare Access and Quality
Collaborators. Healthcare Access and
Quality Index based on mortality from
causes amenable to personal health care in
195 countries and territories, 1990-2015: a
novel analysis from the Global Burden of
Disease
Study
2015.
Lancet.
2017;390(10091):231-66.
Westreich D. Berkson’s bias, selection bias,
and
missing
data.
Epidemiology.
2012;23(1):159-64.
Lobo A, Saz P, Marcos G, Grupo de Trabajo
ZARADEMP.
MMSE.
Examen
Cognoscitivo Mini-Mental. TEA ediciones;
2002.
Blesa R, Pujol M, Aguilar M, Santacruz P,
Bertran-Serra I, Hernández G, et al. Clinical
validity of the ‘mini-mental state’ for
Spanish
speaking
communities.
Neuropsychologia. 2001;39(11):1150-7.

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ANNEXES

i

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ANNEX 1: Project timeline

SPIN cohort
[2010-2017]

Study design
[2018 January]

Data mining
[2018 February]

• Neuropsychological
assessment
• CSF
• Neuroimaging
• Genetic
assessment

• Literature
review*
• Cross-sectional
study design
• Inclusion &
exclusion
criteria
definition
• Statistical
analysis design
• Title

• Database work
• Variables
encoding

Data analysis
[2018 MarchMay]
• SPSS work
• Text editing
• Power Point
design

Presentation
[2018 July]

Publication
[2018 …]

• Project
presentation

• Expand the
sample size
• Multicenter
study
• Find the journal
• Paper submition

*Literature review:
•

Pubmed search:
Search details
("Frontotemporal Dementia"[Mesh]) AND "Sex"[Mesh]
("Frontotemporal Dementia/diagnosis"[Mesh]) AND "Sex"[Mesh]
("frontotemporal dementia"[MeSH Terms] OR ("frontotemporal"[All Fields]
AND "dementia"[All Fields]) OR "frontotemporal dementia"[All Fields]) AND
("sex"[MeSH Terms] OR "sex"[All Fields]) AND ((hasabstract[text] AND
"loattrfull text"[sb]) AND "2008/01/18"[PDAT] : "2018/01/15"[PDAT] AND
"humans"[MeSH Terms])

•

Search results
0
0

98

Relevant papers
1. Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other
dementias. Dialogues Clin Neurosci. 2016;18(4):437–46
2. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The Diagnostic Challenge of
Psychiatric Symptoms in Neurodegenerative Disease. J Clin Psychiatry. 2011 Feb
15;72(2):126–33.
3. Ranasinghe KG, Rankin KP, Lobach I V, Kramer JH, Sturm VE, Bettcher BM, et al.
Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease
stage. Neurology. 2016 Feb 16;86(7):600–10.

ii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ANNEX 2: MMSE (Mini-mental state examination) (34,35)
Paciente...................................................................................................................Edad.........................
Ocupación.................................................................Escolaridad.............................................................
Examinado por..........................................................Fecha......................................................................
ORIENTACIÓN
• Dígame el día...........fecha………Mes....................Estación...............Año.......
•

Dígame el hospital (o lugar) .....................................................planta.........................
Ciudad…………………….........Provincia................................Nación…...................

___5

___5

FIJACIÓN
• Repita estas tres palabras; PELOTA, CABALLO, MANZANA (hasta que las aprenda) ___3
CONCENTRACIÓN Y CÁLCULO
• Si tiene 30 monedas y me va dando de tres en tres ¿cuantas le van quedando?
•

Repita estos tres números: 5,9,2 (hasta que los aprenda). Ahora hacia atrás

___5
___3

MEMORIA
• ¿Recuerda las tres palabras de antes?

___3

LENGUAJE Y CONSTRUCCIÓN
• Mostrar un bolígrafo. ¿Qué es esto ?, repetirlo con un reloj

___2

•

Repita esta frase: EN UN TRIGAL HABÍA CINCO PERROS

___1

•

Una MANZANA y una PERA, son frutas ¿verdad?
¿qué son el ROJO y el VERDE?

___2

•

¿Que son un PERRO y un GATO?

___3

•

Coja este papel con la mano derecha dóblelo y póngalo encima de la mesa

___1

•

Lea esto y haga lo que dice: CIERRE LOS OJOS

___1

•

Escriba una frase

___1

•

Copie este dibujo

___1

Puntuación: ___/35

iii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ANNEX 3: Rascovsky criteria
Neurodegenerative disease
•

Must be present for any FTD clinical syndrome

•

Shows progressive deterioration of behavior and/or cognition by observation or history

Possible bvFTD
•

Three of the features (A–F) must be present; symptoms should occur repeatedly:
o A. Early (within first 3 years) behavioral disinhibition
o B. Early (within first 3 years) apathy or inertia
o C. Early (within first 3 years) loss of sympathy or empathy
o D. Early (within first 3 years) perseverative, stereotyped or compulsive/ritualistic
behavior
o E. Hyperorality and dietary changes
o F. Neuropsychological profile: executive dysfunction with relative sparing of
memory and visuospatial functions

Probable bvFTD
•

All the following criteria must be present to meet diagnosis
o A. Meets criteria for possible bvFTD
o B. Significant functional decline
o C. Imaging results consistent with bvFTD (frontal and/or anterior temporal atrophy
on CT or MRI or frontal hypoperfusion or hypometabolism on SPECT or PET)

Definite bvFTD
•

Criteria A and either B or C must be present to meet diagnosis:
o A. Meets criteria for possible or probable bvFTD
o B. Histopathological evidence of FTLD on biopsy at post mortem
o C. Presence of a known pathogenic mutation

Exclusion criteria for bvFTD
•

Criteria A and B for possible bvFTD must both be answered negatively; criterion C can be
positive for possible bvFTD but must be negative for probable bvFTD:
o A. Pattern of deficits is better accounted for by other nondegenerative nervous system
or medical disorders
o B. Behavioral disturbance is better accounted for by a psychiatric diagnosis
o C. Biomarkers strongly indicative of Alzheimer’s disease or other neurodegenerative
process

iv

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

ANNEX 4: Informed consent
A) CONSENTIMIENTO INFORMADO – PROYECTO COHORTE SPIN
TÍTULO DEL ESTUDIO:
Búsqueda de biomarcadores en el diagnóstico precoz de las demencias degenerativas primarias.
OBJETIVO:
Nos gustaría pedir su permiso para incluirle en este estudio de investigación. El motivo es que usted o
alguien en su familia ha sido diagnosticado de pérdida de memoria, o demencia. El objetivo de este
estudio es aprender más acerca de la evolución, similitudes y diferencias entre las distintas
enfermedades degenerativas que producen pérdida de memoria u otros síntomas similares.
En este estudio esperamos conocer la utilidad de distintos parámetros en el diagnóstico de
enfermedades que alteran la memoria u otras funciones intelectuales. No obstante, algunos de estos
estudios no forman parte de la evaluación rutinaria de los pacientes con pérdida de memoria. Los
resultados tienen interés exclusivamente desde el punto de vista de investigación y por este motivo no
se le comunicarán los resultados de este estudio a menos que tengan relevancia clínica para usted.
PERSONAS DE CONTACTO:
Si tiene preguntas referentes a este estudio puede contactar con los distintos miembros de la Unidad
de Memoria (Dr. Alberto Lleó, Dr. Juan Fortea, Dr. Daniel Alcolea, Dra. María Carmona, Dra. Estrella
Morenas, Dra. Roser Ribosa o Dr. Rafael Blesa):
• Teléfono de estudios de la Unidad de Memoria del Servicio de Neurología del Hospital de
Sant Pau: 618.846.138 (lunes a viernes de 9:00 a 17:00h)
• Correo electrónico Unidad de Memoria: estudismemoria@santpau.cat
PROCEDIMIENTOS:
Si acepta participar y usted ya se visita en la Unidad de Memoria, se revisará su historia clínica y
algunos datos relevantes como edad, diagnóstico, historia familiar y pruebas complementarias. Si usted
no se visita en la Unidad de Memoria se le realizará una evaluación de unos 45 minutos donde se le
preguntarán aspectos relacionados con su salud y se le realizará una evaluación breve de su memoria
y otras facultades intelectuales. Esta información es de gran utilidad para conectar los resultados de la
investigación con los hallazgos médicos.
Durante un período de dos años se realizará un seguimiento clínico mediante visitas médicas
semestrales en la Unidad de Memoria y, además de las pruebas que forman parte de la evaluación
rutinaria de los pacientes con pérdida de memoria, se solicitará su colaboración para la realización de
las siguientes exploraciones:
1. Análisis de sangre: Estas muestras se utilizarán para extraer ADN (el ADN es el material del
que están constituidos los genes) y para analizar los niveles de determinados parámetros en la
sangre. Se realizará un total de 5 extracciones a lo largo de los dos años. Los riesgos derivados
de la extracción de sangre son mínimos, e incluyen dolor leve o un pequeño morado en la zona
de la extracción. Los resultados de estos análisis tienen interés únicamente desde el punto de
vista de investigación, por lo que los resultados no le serán comunicados. Estos análisis son
independientes de la analítica rutinaria que se suele solicitar a todos los pacientes con
problemas de memoria al inicio de su evaluación, y cuyos resultados, sí le serán comunicados.
2. Resonancia Magnética cerebral (RM): La RM cerebral es una prueba de imagen que permite
ver con detalle la estructura de su cerebro sin necesidad de utilizar radiaciones ionizantes en su
adquisición. Frecuentemente esta prueba forma parte de la evaluación rutinaria de los pacientes
v

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

con problemas de memoria. En su caso, se realizará con una doble finalidad: asistencial y de
investigación. Cualquier dato de relevancia clínica le será comunicado en la visita médica
correspondiente. Se realizará una RM al inicio del estudio y posteriormente con una frecuencia
anual (un total de 3). Las contraindicaciones para la realización de esta prueba incluyen: tener
implantado un marcapasos, desfibrilador automático, clips aneurismáticos o cualquier prótesis
metálica no extraíble.
3. Punción lumbar (una al inicio y otra al año de seguimiento): consentimiento independiente.
Para preservar la confidencialidad de esta información, los datos pertenecientes a este estudio
no se incluirán en la historia clínica convencional, sino en un fichero aparte en un lugar
protegido. La información recogida, la muestra de sangre y la de líquido cefalorraquídeo serán
asignadas a un código. La clave de este código será almacenada por el investigador principal
en un archivo independiente. Los resultados de dichas exploraciones se introducirán en una
base de datos independiente creada especialmente para este estudio. En esta base no se utilizará
su nombre, ni ningún otro dato que pueda identificarle a usted, sino sólo el código asignado a
este estudio. La información es totalmente confidencial y sólo será accesible a los miembros
del equipo investigador.
Es posible que le solicitemos que contacte con algún miembro de su familia. En este caso, le daremos
copias de esta carta para que se la entregue a sus familiares para que ellos se pongan en contacto con
nosotros.
Este estudio es totalmente voluntario, puede retirarse cuando lo desee y tiene derecho a solicitar que
toda la información referente a usted, así como la muestra de sangre sea destruida en cualquier
momento. No existen beneficios directos para usted en este estudio, pero es posible que los resultados
de este estudio permitan un mayor conocimiento de la evolución de las enfermedades degenerativas
que ocasionan pérdida de memoria y que pueda contribuir al desarrollo de mejores tratamientos para
curar o prevenir estas enfermedades. No es probable que la información derivada de este estudio tenga
implicaciones directas para su salud. No obstante, si usted lo desea, puede solicitar los resultados de
los estudios realizados con sus muestras.
COSTES:
El estudio no tiene coste económico para usted.
OPCIONES:
1. Nos da permiso para contactar con usted en el futuro para pedirle otra muestra de sangre?
SI__ NO__
2. Nos autorizaría a compartir la información con otro equipo investigador siempre que fuera anónima
(toda la información que pueda identificarle sería eliminada)?
SI__ NO__
FIRMAS:

Paciente, familiar o representante legal (señalar)

Fecha

Médico (Nº colegiado)

Fecha

vi

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

B) CONSENTIMIENTO INFORMADO – PUNCIÓN LUMBAR
El Sr./Sra. ................................................................................................................................................
(escribir el nombre y los dos apellidos)
con DNI nº ................................................ en calidad de ........................................................................
(en caso de minoría de edad o incapacidad, especificar parentesco, tutor o representante legal)
del paciente Sr(a) .....................................................................................................................................
(escribir el nombre y los dos apellidos)
DESCRIPCIÓN DEL PROCEDIMIENTO
La punción lumbar es un procedimiento mediante el cual, se introduce una aguja en el canal medular
para extraer una muestra del líquido en el que está bañado el sistema nervioso central (cerebro y médula
espinal), llamado líquido cefalorraquídeo.
Se realiza mediante la introducción de una aguja en la zona lumbar. Este es el lugar más seguro para
realizar dicha prueba, ya que queda por debajo del extremo final de la médula espinal y no existe riesgo
de dañarla. Su médico le indicará cuál es la posición adecuada que deberá adoptar para la realización
de esta prueba. Frecuentemente se utiliza un anestésico local que reduce al mínimo las molestias de la
punción.
Este es un procedimiento que se realiza prácticamente a diario en el servicio de Neurología.
POR QUÉ
En la práctica clínica habitual, este procedimiento se realiza con la finalidad de diagnosticar una
infección o inflamación del sistema nervioso. En ocasiones también se utiliza para registrar la presión
del líquido o para administrar medicación.
En su caso, pretendemos medir determinados parámetros bioquímicos que pueden estar en relación
con la enfermedad que le ha sido diagnosticada. La determinación de estos parámetros ya está siendo
de utilidad diagnóstica en otros países, y se realiza de manera prácticamente rutinaria en personas que
tienen su misma enfermedad, aunque aquí, por el momento, sólo se realiza con objetivos de
investigación.
RIESGOS DEL PROCEDIMIENTO
Las complicaciones o riesgos que pueden ocurrir como consecuencia de este procedimiento se detallan
a continuación:
La complicación más común (2-5%) es el dolor de cabeza. Se debe a la disminución de presión
secundaria a la extracción de líquido, y algunas maniobras habituales para disminuirlo son el reposo
en cama e ingesta abundante de líquidos durante las horas siguientes a la punción. De todas formas, si
apareciera, puede pedir a la enfermera un calmante.
Las infecciones (meningitis, espondilodiscitis, celulitis) son raras al realizarse en condiciones estériles.
Otras complicaciones poco frecuentes son hematomas locales en el sitio de la punción, apareciendo
con mayor frecuencia en pacientes con enfermedades hematológicas o tratados con fármacos
anticoagulantes. Excepcionalmente se han descrito hematomas intracraneales secundarios a la
hipotensión del LCR, así como la herniación transtentorial, complicación potencialmente mortal y que
puede aparecer en pacientes con algunos procesos intracraneales como grandes masas, procesos que
por medio de la historia clínica y las pruebas complementarias habrán sido razonablemente descartados
en su caso.

vii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

Expone que:
El Dr(a). ................................................................................... del Servicio de NEUROLOGIA me ha
explicado en qué consiste una punción lumbar y cuál es el motivo por el que se me debería realizar.
También me ha informado de las complicaciones generales de este procedimiento y me ha comunicado
que mis riesgos personales son:
...........................................................................................................................................................
...............................................................................................................................
En caso de aparecer alguna de las complicaciones mencionadas, se tomarán por parte del Hospital
todas las medidas necesarias para corregirla.
La información me ha sido dada de forma comprensible y mis preguntas han sido contestadas, por lo
cual autorizo al equipo médico que me trata a realizar la exploración propuesta.
Conozco que, en cualquier momento y sin necesidad de ninguna explicación, puedo revocar el
consentimiento que estoy dando.
FIRMAS:

Paciente, familiar o representante legal (señalar)

Fecha

Médico (Nº colegiado)

Fecha

Barcelona, _____de_______________ del 20____.

viii

medRxiv preprint doi: https://doi.org/10.1101/19005702; this version posted September 11, 2019. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

Sex-related differences in the clinical diagnosis of frontotemporal dementia

C) CONSENTIMIENTO INFORMADO – COLECCIÓN DE MUESTRAS BIOLÓGICAS
El Sr./Sra. ...............................................................................................................................................
(escribir el nombre y los dos apellidos)
con DNI nº .............................................. en calidad de .........................................................................
(en caso de minoría de edad o incapacidad, especificar parentesco, tutor o representante legal)
del paciente Sr(a) ....................................................................................................................................
(escribir el nombre y los dos apellidos)
CONFIRMA QUE:
1. Autoriza a que el material biológico obtenido de los procedimientos explicados en la hoja de
información se guarde en una colección de muestras biológicas con fines de investigación
biomédica.
SI__ NO__
2. Nos autorizaría a compartir la información y las muestras biológicas incluidas con otro equipo
investigador siempre que fueran anónimas (toda la información que pueda identificarle sería
eliminada)?
SI__ NO__
3. Autoriza a ser contactado en el caso de que se requiera más información o muestras
biológicas adicionales.
SI__ NO__ Teléfono o e-mail de contacto:
4. Deseo que se me comunique la información derivada de la investigación que sea
médicamente relevante y aplicable para mi salud o la de mi familia.
SI__ NO__
Teléfono o e-mail de contacto:

FIRMAS:

Paciente, familiar o representante legal (señalar)

Fecha

Médico (Nº colegiado)

Fecha

Barcelona, _____de_______________ del 20____.

ix

